Allena Pharmaceuticals Appoints Gino Santini to Board of Directors
Former Eli Lilly and Company Senior Executive Brings Extensive Line Management, Strategic Planning, Product and Transaction Expertise
NEWTON, Mass. – February 14, 2012 - Allena Pharmaceuticals, Inc., a company developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions, today announced the appointment of Gino Santini to the company’s board of directors. Mr. Santini most recently served as senior vice president of corporate strategy and business development at Eli Lilly and Company, where he led corporate strategy and long-range planning, M&A, new product licensing, innovative financing of internal development projects and the expansion of Lilly Ventures in the U.S. and China.
“It is an honor to welcome Gino to our board of directors,” said Alexey Margolin, Ph.D., co- founder, president and CEO of Allena Pharmaceuticals. “The team that founded Allena has worked with Gino in the past and we know that his strategic insights and proven expertise will be of significant value to Allena as we work to accelerate the development of our non-systemic protein therapeutics.”
Mr. Santini recently retired after a 27-year career at Eli Lilly and Company, where he held positions of increasing responsibility, serving as senior vice president, corporate strategy and policy from 2004 to 2007; president, U.S. operations from 1999 to 2004; and president, women’s health business unit from 1997 to 1999. Mr. Santini contributed significantly as a member of Eli Lilly’s executive team, driving the company’s change agenda, interfacing with the board of directors and serving as an internal and external spokesperson for the company. Mr. Santini is a past chairman of the board of the National Pharmaceutical Council and of Noble of Indiana, a non-profit agency serving individuals with developmental disabilities. He also served on the board of directors for United Way and the executive committee and board of the Indianapolis Chamber of Commerce. He holds a degree in mechanical engineering from the University of Bologna and a Master of Business Administration from the Simon School of Business, University of Rochester.
“I am delighted to join Allena’s board of directors at such a pivotal time in the company’s evolution,” said Mr. Santini. “I know first-hand the Allena team’s proven track record in protein therapeutic design and development, and I look forward working closely with them as they make significant advances in their programs this year.”
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. The company’s proven approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by reducing toxic metabolites without being absorbed into the bloodstream. Led by a proven management team with deep expertise in protein therapeutic design and development, Allena is committed to bringing breakthrough new treatments to patients with unmet medical needs. Based in Newton, Mass., the company is backed by top-tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. For more information, please visit www.allenapharma.com.